Effect of C1q-binding donor-specific anti-HLA antibodies on the clinical outcomes of patients after renal transplantation: A systematic review and meta-analysis

Pascual, 2008, A systematic review of kidney transplantation from expanded criteria donors, Am. J. Kidney Dis., 52, 553, 10.1053/j.ajkd.2008.06.005 Mohan, 2012, Donor-specific antibodies adversely affect kidney allograft outcomes, J. Am. Soc. Nephrol., 23, 2061, 10.1681/ASN.2012070664 Lefaucheur, 2010, Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation, J. Am. Soc. Nephrol., 21, 1398, 10.1681/ASN.2009101065 Lee, 2002, All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies, Transplantation, 74, 1192, 10.1097/00007890-200210270-00025 Valenzuela, 2014, Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms, Curr. Opin. Organ. Transpl., 19, 33, 10.1097/MOT.0000000000000040 Feucht, 1991, Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection, Clin. Exp. Immunol., 86, 464, 10.1111/j.1365-2249.1991.tb02954.x Bohmig, 2002, Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury, J. Am. Soc. Nephrol., 13, 1091, 10.1681/ASN.V1341091 Collins, 1999, Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries, J. Am. Soc. Nephrol., 10, 2208, 10.1681/ASN.V10102208 Otten, 2012, Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure, Am. J. Transplant., 12, 1618, 10.1111/j.1600-6143.2011.03985.x Crespo, 2013, Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?, Transpl. Immunol., 29, 28, 10.1016/j.trim.2013.07.002 Loupy, 2013, Complement-binding anti-HLA antibodies and kidney-allograft survival, N. Engl. J. Med., 369, 1215, 10.1056/NEJMoa1302506 Malheiro, 2017, Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation, Transpl. Int., 30, 347, 10.1111/tri.12873 Thammanichanond, 2014, Significance of C1q-fixing donor-specific antibodies after kidney transplantation, Transplant. Proc., 46, 368, 10.1016/j.transproceed.2013.11.011 Guidicelli, 2016, Non-complement-binding De Novo donor-specific anti-HLA antibodies and kidney allograft survival, J. Am. Soc. Nephrol., 27, 615, 10.1681/ASN.2014040326 Okabe, 2018, Preformed C1q-binding donor-specific anti-HLA antibodies and graft function after kidney transplantation, Transplant. Proc., 50, 3460, 10.1016/j.transproceed.2018.07.033 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med., 6, 10.1371/journal.pmed.1000097 Djamali, 2014, Diagnosis and management of antibody-mediated rejection: current status and novel approaches, Am. J. Transplant., 14, 255, 10.1111/ajt.12589 Hidalgo, 2009, De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure, Am. J. Transplant., 9, 2532, 10.1111/j.1600-6143.2009.02800.x Aubert, 2009, Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant, Hum. Immunol., 70, 580, 10.1016/j.humimm.2009.04.011 Gupta, 2009, Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor, Hum. Immunol., 70, 618, 10.1016/j.humimm.2009.04.020 Lan, 2018, Clinical utility of complement dependent assays in kidney transplantation, Transplantation, 102, S14, 10.1097/TP.0000000000001819 Ginevri, 2012, Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection, Am. J. Transplant., 12, 3355, 10.1111/j.1600-6143.2012.04251.x Lachmann, 2009, Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts, Transplantation, 87, 1505, 10.1097/TP.0b013e3181a44206 Susal, 2015, Association of kidney graft loss with De Novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing, Transplantation, 99, 1976, 10.1097/TP.0000000000000672 Einecke, 2009, The early course of kidney allograft rejection: defining the time when rejection begins, Am. J. Transplant., 9, 483, 10.1111/j.1600-6143.2008.02546.x Lee, 2018, Clinical impact of complement (C1q, C3d) binding De novo donor-specific HLA antibody in kidney transplant recipients, PLoS One, 13, 10.1371/journal.pone.0207434 Hayde, 2021, C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients, Pediatr. Transplant., 25, 10.1111/petr.13885 Thammanichanond, 2016, Role of pretransplant complement-fixing donor-specific antibodies identified by C1q assay in kidney transplantation, Transplant. Proc., 48, 756, 10.1016/j.transproceed.2015.12.116 Lachmann, 2013, Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies, Transplantation, 95, 694, 10.1097/TP.0b013e31827b3dc3 Llorente, 2012, C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG, Transplant. Proc., 44, 2535, 10.1016/j.transproceed.2012.09.084 Malheiro, 2017, Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation, Transpl. Int., 30, 347, 10.1111/tri.12873 Kauke, 2017, De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability, Transpl. Int., 30, 360, 10.1111/tri.12887 Calp-Inal, 2016, The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation, Kidney Int., 89, 209, 10.1038/ki.2015.275 Baranwal, 2021, Impact of C1q fixing donor-specific antibodies on renal transplant outcome, Scand. J. Immunol., 94, 10.1111/sji.13048 Moktefi, 2017, C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study, Transpl. Int., 30, 277, 10.1111/tri.12905 Wiebe, 2017, Evaluation of C1q status and titer of De novo donor-specific antibodies as predictors of allograft survival, Am. J. Transplant., 17, 703, 10.1111/ajt.14015 Yabu, 2011, C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation, Transplantation, 91, 342, 10.1097/TP.0b013e318203fd26 Yell, 2015, C1q binding activity of De novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection, Transplantation, 99, 1151, 10.1097/TP.0000000000000699 Kim, 2018, Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies, Pediatr. Nephrol., 33, 167, 10.1007/s00467-017-3772-7 Fichtner, 2016, Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients, Pediatr. Nephrol., 31, 1157, 10.1007/s00467-016-3322-8 Molina, 2017, Impact of preformed donor-specific anti-human leukocyte antigen antibody C1q-binding ability on kidney allograft outcome, Front. Immunol., 8, 1310, 10.3389/fimmu.2017.01310 Messina, 2015, Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy, Transpl. Immunol., 33, 7, 10.1016/j.trim.2015.06.002 Schaefer, 2016, Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients, Hla, 87, 89, 10.1111/tan.12735 Crespo, 2013, Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?, Transpl. Immunol., 29, 28, 10.1016/j.trim.2013.07.002 Sutherland, 2012, Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss, Pediatr. Transplant., 16, 12, 10.1111/j.1399-3046.2011.01599.x Ponsirenas, 2018, Anti-HLA donor-specific IgG subclasses and C1q-binding evolution in Posttransplant monitoring, Transpl. Direct, 4, 10.1097/TXD.0000000000000823 Malheiro, 2018, Detection of complement-binding donor-specific antibodies, not IgG-antibody strength nor C4d status, at antibody-mediated rejection diagnosis is an independent predictor of kidney graft failure, Transplantation, 102, 1943, 10.1097/TP.0000000000002265 Bamoulid, 2017, Clinical outcome of patients with De novo C1q-binding donor-specific HLA antibodies after renal transplantation, Transplantation, 101, 2165, 10.1097/TP.0000000000001487 Cazarote, 2018, Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure, Transpl. Immunol., 49, 33, 10.1016/j.trim.2018.03.002 Cicciarelli, 2017, Renal transplant patients biopsied for cause and tested for C4d, DSA, and IgG subclasses and C1q: which humoral markers improve diagnosis and outcomes?, J Immunol Res, 2017, 1652931, 10.1155/2017/1652931